1 / 21

Sotalol

Sotalol Pediatric Decision Tree and Exposure-Response Relationship Peter Hinderling, OCPB Saul et al. JCP 2001;40:35-43 Saul et al. CPT 2001;69:145-57 Shi et el. JPK PD 2001;28:555-75. Sotalol . Adults 1992 : Life threatening VT, VF (Betapace ®)

ziya
Download Presentation

Sotalol

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Sotalol Pediatric Decision Tree and Exposure-ResponseRelationshipPeter Hinderling, OCPBSaul et al. JCP 2001;40:35-43Saul et al. CPT 2001;69:145-57Shi et el. JPK PD 2001;28:555-75

  2. Sotalol Adults 1992 : Life threatening VT, VF (Betapace ®) 2000 : Maintenance of SR in sympt. AFIB/AFL (Betapace AF ™) PK: Linear F: 90% Ae/D=90 % t1/2 = 12 h PK-PD: Linear dl Sotalol : Class III antiarrythmic act. l Sotalol : -blocking act.

  3. Knowledge on Sotalol in Pediatrics in 1999 • Published, uncontrolled studies in children using adult doses adjusted for BSA or BW and  =12 h Breakthrough arrhythmias with  =12 h

  4. Lipicky Paradigm (Pediatric Summit, Washington, 2002): “ Do what is feasible in children, see what can be extracted and use it.” “ In the case of antiarrhythmics where the demonstration of efficacy even in adults is shaky, it is not reasonable to ask for efficacy in children.”

  5. PD Biomarkers • Class III / safety:QTc- Interval • Class II /safety: Resting RR-Interval

  6. Written Request • PK :Open label, single dose study, 1 dose level, extensive sampling,  6 N,  10 I,  10 PC,  10 SC • PK-PD : Open label, multiple ascending dose study, 3 dose levels, sparse sampling,  8 N or  8 I completing

  7. Study Protocols

  8. Methods • Formulation: Syrup, extemporaneous compounding procedure • Assay: LC/MS/MS, 0.4 ml blood required • ECG: Same type in all sites Baseline values during 8 h dose interval Blinded cardiologist, digitizing pad QTc Fridericia, Bazett • Data analysis: Traditional and population approaches PK: Linear 2 CM PK-PD: Linear and Emax models

  9. Study Sites and Database Sites 24 sites initiated for PK study 21 sites initiated for PK-PD study 59 patients enrolled (34 in PK study, 25 in PK-PD study) 54 SVT, 3 VT, 2 SVT & VT Database 58 patients with analyzable PK data ( 9 N, 17 I, 9 PC, 23 SC) 22 patients with analyzable PD data ( 6 N, 8 I, 3 PC, 5 SC)

  10. Representative Semilogarithmic Plots of Sotalol Plasma Concentrations

  11. Relationship between CL/f and Vc/f and BSA(Empirical Bayes Estimates)

  12. Plot of Dose and BSA Normalized AUC vs. BSA for 58 Pediatric Patients and 40 Adults

  13. Dose-Response Relationship

  14. Impact of BSA on PK

  15. Consequential Impact of BSA on PD

  16. Representative Plots of Observed QTc Intervals vs. (Empirical Bayes) Predicted Sotalol Concentrations in 4 Individuals

  17. Representative Plots of Observed RR Intervals vs. (Empirical Bayes) Predicted Sotalol Concentrations in 4 Individuals

  18. Summary of Results • PK -Linear and dose proportionate - t1/2  10 hours, independent of BSA - CL/f and Vc/f linearly dependent on BSA - BSA most important covariate - Greater exposure of smallest children (BSA < 0.33 m2 ) • PD, PK-PD • - Doses tolerated well - Responses increase dose dependently - Pharmacologically important effects: Class III at 70 mg/m2, -blocking at 30 and 70 mg/m2 - Trend for greater effects in smallest children - Effects linearly correlated with concentrations -blocking effect increases with BSA

  19. Additional Dose Adjustment Factor in N and I

  20. Conclusions Exposure-response analysis in children using biomarkers: PS and SC: “Small adults”, similar exposure and responseas adults, BSA based dose adjustment appropriate N and I: Subpopulation with larger exposureand response Maturation of kidney Additional dose adjustment required

More Related